Carvedilol protects the infarcted heart by upregulating miR-133: First evidence that disease state affects β-adrenergic arrestin-biased signaling?

Current Therapeutic Research - Clinical and Experimental

Volumn 76, Issue , 2014, Pages 12-14

  Kurdi, Mazen ^a,b,c   Booz, George W ^b,c  

^a LEBANESE UNIVERSITY   (Lebanon)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; CARVEDILOL; CASPASE 9; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; MICRORNA; MICRORNA 133; REACTIVE OXYGEN METABOLITE; RIBONUCLEASE III; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ACUTE HEART INFARCTION; ANTIOXIDANT ACTIVITY; CORONARY ARTERY DISEASE; EDITORIAL; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; UPREGULATION; ANIMAL; APOPTOSIS; CELL PROTECTION; DRUG EFFECTS; GENETICS; MALE; PATHOLOGY;

ANIMALS; APOPTOSIS; CARBAZOLES; CYTOPROTECTION; MALE; MICRORNAS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROPANOLAMINES; UP-REGULATION;

EID: 84907486448     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.08.004     Document Type: Editorial

References (30)

1. Judd S.E., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292. 10.1161/01.cir.0000441139.02102.80.
2. Ambrosy A.P., Fonarow G.C., Butler J., Chioncel O., Greene S.J., Vaduganathan M., et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014, 63:1123-1133. 10.1016/j.jacc.2013.11.053.
3. Gaziano T.A. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005, 112:3547-3553. 10.1161/CIRCULATIONAHA.105.591792.
4. Heidenreich P.A., Albert N.M., Allen L.A., Bluemke D.A., Butler J., Fonarow G.C., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013, 6:606-619. 10.1161/HHF.0b013e318291329a.
5. Velagaleti R.S., Vasan R.S. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem?. Cardiol Clin 2007, 25:487-495. 10.1016/j.ccl.2007.08.010.
6. Kannel W.B., Cobb J. Left ventricular hypertrophy and mortality-results from the Framingham Study. Cardiology 1992, 81:291-298.
7. Poirier L., Tobe S.W. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol 2014, 30:S9-S15. 10.1016/j.cjca.2013.12.001.
8. Boudonas G.E. β-blockers in coronary artery disease management. Hippokratia 2010, 14:231-235.
9. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106:2194-2199. 10.1161/01.CIR.0000035653.72855.BF.
10. DiNicolantonio J.J., Lavie C.J., Fares H., Menezes A.R., O'Keefe J.H. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol 2013, 111:765-769. 10.1016/j.amjcard.2012.11.031.
11. Vanhoutte P.M., Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013, 13:265-273. 10.1016/j.coph.2012.12.002.
12. Octavia Y., Brunner-La Rocca H.P., Moens A.L. NADPH oxidase-dependent oxidative stress in the failing heart: from pathogenic roles to therapeutic approach. Free Radic Biol Med 2012, 52:291-297. 10.1016/j.freeradbiomed.2011.10.482.
13. Zhang M., Perino A., Ghigo A., Hirsch E., Shah A.M. NADPH oxidases in heart failure: poachers or gamekeepers?. Antioxid Redox Signal 2013, 18:1024-1041. 10.1089/ars.2012.4550.
14. Feuerstein G.Z., Yue T.L., Cheng H.Y., Ruffolo R.R. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl 1993, 11:S41-S48.
15. Chen-Scarabelli C., Saravolatz L., Murad Y., Shieh W.S., Qureshi W., Di Rezze J., et al. A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs 2012, 12:391-401. 10.2165/11636090-000000000-00000.
16. DiNicolantonio J.J., Hackam D.G. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker. Expert Rev Cardiovasc Ther 2012, 10:13-25. 10.1586/erc.11.166.
17. Xu C., Hu Y., Hou L., Ju J., Li X., Du N., et al. β-blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J Mol Cell Cardiol 2014, [July]. 10.1016/j.yjmcc.2014.07.009.
18. 1-adrenergic receptor signaling regulates microRNA processing. Circ Res 2014, 114:833-844. 10.1161/CIRCRESAHA.114.302766.
19. Reiter E., Ahn S., Shukla A.K., Lefkowitz R.J. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 2012, 52:179-197. 10.1146/annurev.pharmtox.010909.105800.
20. 2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci Signal 2011, 4:ra51. 10.1126/scisignal.2001707.
21. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., et al. A unique mech anism of β-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 2007, 104:16657-16662. 10.1073/pnas.0707936104.
22. Kim I.M., Tilley D.G., Chen J., Salazar N.C., Whalen E.J., Violin J.D., et al. β-blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 2008, 105:14555-14560. 10.1073/pnas.0804745105.
23. Oliveira-Carvalho V., da Silva M.M., Guimarães G.V., Bacal F., Bocchi E.A. MicroRNAs: new players in heart failure. Mol Biol Rep 2013, 40:2663-2670. 10.1007/s11033-012-2352-y.
24. Han M., Toli J., Abdellatif M. MicroRNAs in the cardiovascular system. Curr Opin Cardiol 2011, 26:181-189. 10.1097/HCO.0b013e328345983d.
25. Bostjancic E., Zidar N., Stajer D., Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010, 115:163-169. 10.1159/000268088.
26. Matkovich S.J., Wang W., Tu Y., Eschenbacher W.H., Dorn L.E., Condorelli G., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010, 106:166-175. 10.1161/CIRCRESAHA.109.202176.
27. 1-adrenergic receptor transduction cascade. Circ Res 2014, 115:273-283. 10.1161/CIRCRESAHA.115.303252.
28. 2+/calmodulin kinase II. J Clin Invest 2003, 111:617-625. 10.1172/JCI16326.
29. Zhang X., Szeto C., Gao E., Tang M., Jin J., Fu Q., et al. Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. Circ Res 2013, 112:498-509. 10.1161/CIRCRESAHA.112.273896.
30. 1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2009, 297:H1377-H1386. 10.1152/ajpheart.00504.2009.